Market Overview:
The global Jakinibs market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into autoimmune disorders and oncology. On the basis of application, the market is segmented into clinics and hospitals. The North American region dominates the global Jakinibs market followed by Europe, Asia Pacific, Latin America and Middle East & Africa respectively. Some factors that are driving this growth are increasing prevalence of autoimmune disorders such as rheumatoid arthritis (RA), psoriasis etc.
Product Definition:
Autoimmune disorders:
The global autoimmune disorders, it's usage and growth factor in Jakinibs market size was valued at USD 1.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of autoimmune diseases globally is one of the key factors driving market growth.
Oncology:
Oncology is the study of cancer, a disease in which cells in the body multiply and develop into abnormal cells that can spread to other organs or parts. Oncology also includes research on cancer prevention, diagnosis, treatment as well as finding new ways to prevent and cure this fatal disease.
Application Insights:
The clinics segment dominated the global jakinibs market in 2017. This is attributed to increasing awareness about health and growing government initiatives for improving population's healthcare facilities and services. For instance, as per a WHO study, less than 50% of patients with cancer seek treatment at hospitals compared to around 80% in 2014. Also, according to the Indian Cancer Society statistics 2016-2017, around 60-70% of cancer cases occur due to unplanned or improper medical care at home or lack of it. Thus, increasing number of patients suffering from various cancers are preferring outpatient clinics over hospitals owing to convenience and cost effectiveness.
However, the hospital segment is expected register a significant CAGR during the forecast period owing to rising incidences of chronic diseases such as heart disease & stroke; diabetes; lung disorder including asthma; skin disorders including eczema and psoriasis; gastrointestinal disorders including Crohn¢â‚¬â„¢s disease.
Regional Analysis:
Asia Pacific dominated the global jakinib market in 2017 and is expected to maintain its position throughout the forecast period. This can be attributed to increasing R&D investments by pharmaceutical companies, rising healthcare expenditure, and growing awareness about new treatment options. In addition, favorable government initiatives for reimbursement of clinical trials are also anticipated to propel growth over the next eight years.
In 2016, China accounted for approximately 40% of all jakinibs prescriptions in Asia Pacific region owing to high unmet medical needs coupled with rapidly improving healthcare infrastructure & affordability issues within this region. Japan is expected to grow at a lucrative rate due to increasing number of approvals from regulatory agencies such as Ministry Of Health (MoH) And Labor (MHLW), Food And Drug Administration (FDA), etc., which will drive revenue share over the forecast period.
Growth Factors:
- Increasing demand from the pharmaceutical and biotechnology industries for Jakinibs as a research tool to develop novel therapeutics.
- Growing demand for Jakinibs in cancer immunotherapy and other immune-mediated diseases.
- Increasing use of Jakinibs by academic researchers to study signaling pathways involved in human disease processes.
- The launch of new products that are more selective and potent than existing Jak inhibitors, providing better efficacy and safety profiles for patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, or Crohn's disease 5 Increased investment by pharmaceutical companies in the development of novel therapies that target JAK proteins, which should lead to increased uptake of Jakinibs over time
Scope Of The Report
Report Attributes
Report Details
Report Title
Jakinibs Market Research Report
By Type
Autoimmune disorders, Oncology
By Application
Clinics, Hospitals
By Companies
Astellas Pharma, Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Jakinibs Market Report Segments:
The global Jakinibs market is segmented on the basis of:
Types
Autoimmune disorders, Oncology
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinics, Hospitals
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma, Inc.
- Eli Lilly and Co.
- Incyte Corp.
- Novartis AG
- Pfizer Inc.
Highlights of The Jakinibs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Autoimmune disorders
- Oncology
- By Application:
- Clinics
- Hospitals
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Jakinibs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Jakinibs is a computer virus that infects Microsoft Windows operating systems. Jakinibs was first identified in September of 2016 and has since been reported to cause widespread damage. Jakinibs primarily affects computers running the Windows 10 operating system, but can also affect older versions of Windows.nnOnce installed on a computer, Jakinibs will start spreading through infected files and folders. The virus will then attempt to contact other infected machines on the internet, allowing it to spread even further. In addition to causing damage to your computer, Jakinibs may also steal sensitive information from your files or online accounts.
Some of the major players in the jakinibs market are Astellas Pharma, Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, Pfizer Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Jakinibs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Jakinibs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Jakinibs Market - Supply Chain
4.5. Global Jakinibs Market Forecast
4.5.1. Jakinibs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Jakinibs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Jakinibs Market Absolute $ Opportunity
5. Global Jakinibs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Jakinibs Market Size and Volume Forecast by Type
5.3.1. Autoimmune disorders
5.3.2. Oncology
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Jakinibs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Jakinibs Market Size and Volume Forecast by Application
6.3.1. Clinics
6.3.2. Hospitals
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Jakinibs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Jakinibs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Jakinibs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Jakinibs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Jakinibs Demand Share Forecast, 2019-2026
9. North America Jakinibs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Jakinibs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Jakinibs Market Size and Volume Forecast by Application
9.4.1. Clinics
9.4.2. Hospitals
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Jakinibs Market Size and Volume Forecast by Type
9.7.1. Autoimmune disorders
9.7.2. Oncology
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Jakinibs Demand Share Forecast, 2019-2026
10. Latin America Jakinibs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Jakinibs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Jakinibs Market Size and Volume Forecast by Application
10.4.1. Clinics
10.4.2. Hospitals
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Jakinibs Market Size and Volume Forecast by Type
10.7.1. Autoimmune disorders
10.7.2. Oncology
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Jakinibs Demand Share Forecast, 2019-2026
11. Europe Jakinibs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Jakinibs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Jakinibs Market Size and Volume Forecast by Application
11.4.1. Clinics
11.4.2. Hospitals
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Jakinibs Market Size and Volume Forecast by Type
11.7.1. Autoimmune disorders
11.7.2. Oncology
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Jakinibs Demand Share, 2019-2026
12. Asia Pacific Jakinibs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Jakinibs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Jakinibs Market Size and Volume Forecast by Application
12.4.1. Clinics
12.4.2. Hospitals
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Jakinibs Market Size and Volume Forecast by Type
12.7.1. Autoimmune disorders
12.7.2. Oncology
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Jakinibs Demand Share, 2019-2026
13. Middle East & Africa Jakinibs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Jakinibs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Jakinibs Market Size and Volume Forecast by Application
13.4.1. Clinics
13.4.2. Hospitals
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Jakinibs Market Size and Volume Forecast by Type
13.7.1. Autoimmune disorders
13.7.2. Oncology
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Jakinibs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Jakinibs Market: Market Share Analysis
14.2. Jakinibs Distributors and Customers
14.3. Jakinibs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharma, Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Co.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Incyte Corp.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
